Epigenetic heterogeneity promotes acquired resistance to BET bromodomain inhibition in ovarian cancer.
Sun Y, Zhang Z, Zhang K, Liu Y, Shen P, Cai M, Jia C, Wang W, Gu Z, Ma P, Lu H, Guan L, Di W, Zhuang G, Yin X.
Sun Y, et al.
Am J Cancer Res. 2021 Jun 15;11(6):3021-3038. eCollection 2021.
Am J Cancer Res. 2021.
PMID: 34249442
Free PMC article.